Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
We recently published
Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer.
Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks. Throughout 2025, the CNBC TV regularly praised the firm for a multitude of factors. These included its lead in the weight loss drug race, a diverse product portfolio, and efforts to establish a robust manufacturing presence in America. Eli Lilly and Company (NYSE:LLY)’s shares are up by 40% over the past year and by 5% year-to-date. Jefferies discussed the firm on June 9th as it raised the share price target to $1,350 from $1,330 and kept a Buy rating on the stock. The coverage was based on Eli Lilly and Company (NYSE:LLY)’s retatrutide drug, which the bank noted would be difficult to compete against in the obesity market. Cramer discussed the firm in a brief tweet on June 8th:
“Not selling LLY but i understand reluctance to buy it here. My sunday piece is good explainer as CNBC Investing Club members know”
Pixabay/Public domain
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
